Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer

Yuan, Yuanying; Niu, Lizhi; Feng, Ming; Wang, Xiaohua; Zhang, Jianying; Yao, Fei; Jiang, Feng; He, Liyun; Chen, Jibing; Li, Jialiang; Xu, Kecheng

doi:10.1016/j.cryobiol.2013.08.001

Cited by 52 publications

(48 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are in harmony with results from other studies, which showed that DC-CIK therapy increased the survival rates and progression free survival, compared to placebo, no intervention, conventional treatments, or other complementary and alternative medicines (Chen et al, 2014). Yuanying et al also showed that combining cryosurgery, chemotherapy or DC therapy with activated CIK immunotherapy can help prolong the median overall survival of patients (Yuanying et al, 2013).…”

Section: Cik Cell With Dendritic Cell (Dc)supporting

confidence: 71%

Cytokine-induced killer cell transplantation: an innovative adoptive therapy

Phan

Pham

2016

Biomed Res Ther

View full text Add to dashboard Cite

show abstract

Section: Cik Cell With Dendritic Cell (Dc)supporting

confidence: 71%

Cytokine-induced killer cell transplantation: an innovative adoptive therapy

Phan

Pham

2016

Biomed Res Ther

View full text Add to dashboard Cite

show abstract

“…Although few studies have examined DTA, several have reported on the combination of cryoablation or heat thermal therapy with other methods, including radiation, chemotherapy (e.g. FOLFIRINOX) and excision, yielding improved outcome [15,[41][42][43][44][45]. As such, we examined the combination of heat and freezing on PaCa.…”

Section: Discussionmentioning

confidence: 99%

Dual thermal ablation of pancreatic cancer cells as an improved combinatorial treatment strategy

Baumann¹,

Baust²,

Snyder³

et al. 2017

Liver Pancreat Sci

View full text Add to dashboard Cite

Pancreatic cancer (PaCa) is one of the leading causes of cancer related deaths in the world today. It is estimated that 95% of patients diagnosed with PaCa will die because of limited treatment options. As standard treatments have not yielded an improvement in patient outcome, alternative approaches, such as thermal ablation, may offer a new treatment path. We previously reported the lethal temperatures necessary for PaCa ablation for both freeze and heat based treatments. In this study, we investigated the response of PaCa cells in vitro to a combination treatment of heating and freezing, dual thermal ablation (DTA), in an effort to further improve ablation efficacy.PaCa cell lines, PANC-1 and BxPC-3, were subjected to heating (45 to 50°C), freezing (-10 to -20°C), or DTA exposure. Post-exposure viability was assessed over a 7-day recovery interval. Modes of cell death were analyzed using fluorescence microscopy and flow cytometry.Our results indicated that in comparison to single thermal modalities, DTA resulted in greater cell destruction at a more rapid rate. Specifically, -15°C had a moderate impact on day one cell viability (PANC-1=80%; BxPC-3=21%) and 50°C (PANC-1=74%; BxPC-3=18%) caused a slow decline in cell number post-treatment. The combination of these treatments resulted in an increased cell death one-day post-treatment (PANC-1=28%; BxPC-3=5%) and achieved complete cell destruction within three days. Overall, these data suggest that a combination of heat and freeze ablation, DTA, may provide for an improved treatment strategy for PaCa.

show abstract

“…The present findings suggest that immunotherapy with DC-CIK has antitumor effects and, in combination with conventional treatment therapies, may prolong the OS time of advanced NSCLC patients (32,34).…”

Section: Discussionmentioning

confidence: 90%

Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer

et al. 2016

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the survival time, immune response and safety of a dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy (DC-CIK) in advanced non-small cell lung cancer (NSCLC). The present retrospective study enrolled 507 patients with advanced NSCLC; 99 patients received DC-CIK [immunotherapy group (group I)] and 408 matched patients did not receive DC-CIK, and acted as the control [non-immunotherapy group (group NI)]. Delayed-type hypersensitivity (DTH), quality of life (QOL) and safety were analyzed in group I. The follow-up period for the two groups was 489.2±160.4 days. The overall survival (OS) time was calculated using the Kaplan-Meier method. DTH was observed in 59 out of 97 evaluated patients (60.8%) and 67 out of 98 evaluated patients (68.4%) possessed an improved QOL. Fever and a skin rash occurred in 36 out of 98 patients (36.7%) and 7 out of 98 patients (7.1%) in group I. DTH occurred more frequently in patients with squamous cell carcinoma compared with patients with adenocarcinoma (77.1 vs. 40.4%; P=0.0013). Radiotherapy was not associated with DC-CIK-induced DTH (72.7 vs. 79.6%; P=0.18), but chemotherapy significantly reduced the rate of DTH (18.2 vs. 79.6%; P=0.00). The OS time was significantly increased in group I compared with group NI (P=0.03).In conclusion, DC-CIK may induce an immune response against NSCLC, improve the QOL, and prolong the OS time of patients, without adverse effects. Therefore, the present study recommends DC-CIK for the treatment of patients with advanced NSCLC. IntroductionLung cancer is the leading cause of cancer-associated mortality and the most common cancer type worldwide (1). In total, ~80% of all lung cancer cases are non-small cell lung cancer (NSCLC) (2), for which surgery, chemotherapy and radiotherapy remain the standard treatments (3). The majority of patients with NSCLC are not recommended for surgery, since patients are often diagnosed at an advanced stage of disease (stage IIIb or IV). Patients that do undergo radical surgery may eventually develop locoregional recurrence or distant metastasis (4). Characterized by inexorable disease progression, advanced NSCLC usually has a high malignant potential. Its prognosis is poor and the clinical onset is extensive, despite treatment with chemotherapy and radiation (5). Systemic chemotherapy is the recommended first-line treatment for patients with advanced stage and metastatic NSCLC, but it is often considered ineffective or excessively toxic (6).Multidisciplinary approaches are required to develop novel treatments for advanced NSCLC (7). One of these multidisciplinary approaches is immunotherapy (7,8), an important and effective method in cancer treatment, particularly for advanced-stage disease (9). Immune cells, including cytokine-induced killer (CIK) cells and dendritic cells (DCs), aid in mounting an effective immune response against cancer cells and kill cancer cells, including residual cells (10-13). A combination of conventional methods, such as surgery...

show abstract

Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer

Cited by 52 publications

References 46 publications

Cytokine-induced killer cell transplantation: an innovative adoptive therapy

Cytokine-induced killer cell transplantation: an innovative adoptive therapy

Dual thermal ablation of pancreatic cancer cells as an improved combinatorial treatment strategy

Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer

Contact Info

Product

Resources

About